Usage Examples
- We filed the EU CTA through CTIS the same week the US IND went in.
- Day 28 on the Canadian CTA and no objection notice, so the site can start ordering drug.
- That trial was never transitioned off the Directive, so its authorisation basis lapsed in January 2025.
What is Clinical Trial Application (CTA)?
Clinical Trial Application (CTA) is the authorisation dossier a sponsor files with a national or EU regulator before dosing the first subject in a trial of an investigational medicinal product, the non-US counterpart to an FDA IND.
A Clinical Trial Application exists because no sponsor gets to put an investigational medicine into humans on its own judgement. A competent authority has to see the protocol, the product quality data, and the accumulated safety record first, and an ethics body has to accept the risk being asked of subjects. The CTA is the vehicle that carries that package to the regulator before enrolment opens.
A Clinical Trial Application authorises the study, not the product. In the EU and EEA it runs under Regulation (EU) No 536/2014, and since 31 January 2023 every application must go through the Clinical Trials Information System. Canada uses the same term for its own filing under the Food and Drug Regulations. A CTA does not cover US trials, which take an IND, and it never confers permission to market.
A Clinical Trial Application in the EU is now filed once and assessed once: the Regulation replaced country-by-country submissions with a single submission via a single EU portal and an assessment leading to a single decision. In Canada, the sponsor files under section C.05.005 and may sell or import the trial drug if no notice barring it arrives within 30 days of receipt. Sponsors running global programmes hold CTA and IND content in step so one protocol survives both reviews.
Not to be confused with
- IND
- an IND opens a trial with FDA in the United States; a CTA authorises the same trial in the EU, EEA, or Canada. A global programme normally needs both, not one instead of the other.
- CTIS
- CTIS is the portal, the CTA is the dossier submitted through it. "We filed in CTIS" names the channel, not the application, and the two are not interchangeable in a regulatory commitment.
- Marketing Authorisation Application
- an MAA asks permission to sell a medicine; a CTA asks permission to study one. Different evidence bar, different dossier, different decision.
- Directive 2001/20/EC
- the superseded EU framework, which required a separate application in each member state. Trials still running under it had to comply with Regulation (EU) No 536/2014 from 31 January 2025.
The obligations depend on where the trial runs. These are the anchors in the two jurisdictions that use the CTA name.
What you must do
- 1Submit every EU or EEA clinical trial application through the Clinical Trials Information System rather than to national authorities individuallyRegulation (EU) No 536/2014
- 2File one dossier covering all Member States concerned and accept the single decision the assessment produces, instead of managing parallel national approvalsRegulation (EU) No 536/2014, single authorisation procedure
- 3Transition any trial still running under the Clinical Trials Directive onto the Regulation, a hard requirement since 31 January 2025Regulation (EU) No 536/2014 transition deadline, 31 January 2025
- 4In Canada, file the application under section C.05.005 and hold sale or import of the trial drug until 30 days pass from receipt without a notice barring itFood and Drug Regulations, C.05.006
- 5Obtain Research Ethics Board approval of the protocol and informed consent form for each Canadian trial site before that site startsFood and Drug Regulations, C.05.006
- 6Prepare submitted content for disclosure, because anybody can view EU and EEA trial information held in CTIS through its searchable public websiteCTIS
Common mistakes
Treating the CTA as an IND with a different cover page
the scientific content overlaps, but the structure and the deciding authority do not. Repackaging an FDA-shaped dossier for CTIS invites requests for information and pushes first-patient-in out by weeks on a trial that was otherwise ready.
Leaving legacy trials on the Directive
trials authorised under Directive 2001/20/EC that were still running had to comply with Regulation (EU) No 536/2014 from 31 January 2025. A study never transitioned into CTIS is operating outside a current authorisation basis, and the fix is not retroactive.
Forgetting the record is public
anybody can view CTIS information on EU and EEA trials through the searchable public website. Redaction and deferral decisions have to be made before the CTA is submitted, not after a competitor reads the synopsis.
When This Matters
- We filed the EU CTA through CTIS the same week the US IND went in.
- Day 28 on the Canadian CTA and no objection notice, so the site can start ordering drug.
- That trial was never transitioned off the Directive, so its authorisation basis lapsed in January 2025.
Frequently Asked Questions
A CTA authorises a clinical trial outside the United States, while an IND opens the same trial with FDA inside it. The scientific content overlaps heavily, since both carry the protocol, product quality data, and accumulated safety information, but the filing route and the deciding authority differ. Global programmes normally run both.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
